Clinical Trial

Fibromyalgia Response With Esreboxetine Evaluated Using a Randomized Withdrawal Research Design

Name: Fibromyalgia Response With Esreboxetine Evaluated Using a Randomized Withdrawal Research Design — clinical trial record (NCT07398417)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: FORWARD

Recruiting Phase 3

View on ClinicalTrials.gov →

Summary

The study is a Phase 3, double-blind, placebo-controlled, randomized withdrawal study to assess the efficacy and safety of AXS-14 in the management of fibromyalgia.

Protocol Amendment History 1 change

notable Trial sites expanded: 16 -> 51 locations 2026-07-25

Trial Details

NCT Number	NCT07398417
Lead Sponsor	Axsome Therapeutics, Inc.
Conditions	Fibromyalgia
Enrollment	620 participants
Start Date	2026-01-14
Primary Completion	2028-03 (estimated)
Study Completion	2028-03 (estimated)
Updated on ClinicalTrials.gov	2026-07-24